Cytokinetics Announces Call for Proposals for Corporate Giving Program
2024年7月30日 - 8:30PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a
call for proposals for the Cytokinetics Corporate Giving Program.
The program provides charitable donations to eligible non-profit
organizations in the United States to support diversity in science
education, equitable healthcare initiatives for cardiovascular
disease and certain essential services for local and at-risk
communities.
“For more than 25 years, our company has proudly
championed patient advocacy, diversity, equity and inclusion
initiatives, as well as research in our therapeutic focus areas of
interest, and we have provided funding to non-profit organizations
devoted to our shared mission,” said Diane Weiser, Cytokinetics’
Senior Vice President, Corporate Affairs. “We are pleased to now
evolve our Corporate Giving Program to align with our maturing
Corporate Responsibility interests and to provide additional
support for an expanded array of giving priorities to make
meaningful and lasting impact for stakeholders.”
The Cytokinetics Corporate Giving Program
consists of individual charitable donations up to $20,000 for
qualified 501(c)(3) organizations in the United States that are
neither engaged, nor directly involved in the practice of
healthcare. Specifically, the program will provide funding to
organizations with initiatives focused on diversity in science
education and certain essential services for local and at-risk
communities in the San Francisco Bay Area and Greater Philadelphia
Region. Additionally, it will support eligible organizations
dedicated to health equity initiatives in cardiovascular disease
across the United States. Applications may now be submitted online
at
https://www.cybergrants.com/Cytokinetics/corporate_giving_eligibility.
The deadline to apply for the Cytokinetics Corporate Giving Program
is September 16, 2024. For more information on the program,
including eligibility details, guidelines and specifics, visit
https://cytokinetics.com/responsibility/grants-and-giving-programs/corporate-giving-program/.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing muscle biology-directed drug
candidates as potential treatments for debilitating diseases in
which cardiac muscle performance is compromised. As a leader in
muscle biology and the mechanics of muscle performance, the company
is developing small molecule drug candidates specifically
engineered to impact myocardial muscle function and contractility.
Cytokinetics is preparing for regulatory submissions for aficamten,
its next-in-class cardiac myosin inhibitor, following positive
results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in
obstructive hypertrophic cardiomyopathy. Aficamten is also
currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of
aficamten as monotherapy compared to metoprolol as monotherapy in
patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial
of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a
clinical trial of aficamten in a pediatric population with
obstructive HCM, and FOREST-HCM, an open-label extension clinical
study of aficamten in patients with HCM. Cytokinetics is also
developing omecamtiv mecarbil, a cardiac muscle activator, in
patients with heart failure. Additionally, Cytokinetics is
developing CK-586, a cardiac myosin inhibitor with a mechanism of
action distinct from aficamten for the potential treatment of
HFpEF, and CK-136, a cardiac troponin activator for the potential
treatment HFrEF and other types of heart failure, such as right
ventricular failure resulting from impaired cardiac
contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in
this press release speak only as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of
Cytokinetics in the U.S. and certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice President,
Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
過去 株価チャート
から 7 2024 まで 7 2024
Cytokinetics (NASDAQ:CYTK)
過去 株価チャート
から 7 2023 まで 7 2024